Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Februar 2024

Genmab — Februar 2024

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • E Offline
    E Offline
    E_L
    wrote on sidst redigeret af
    #13

    So if i calculate that correct that's roughly $851mn growth for ocrevus this year vs $1079mn for Kesimpta

    1 Reply Last reply
    0
    • Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktørH Offline
      Helge_LarsenPI-redaktør
      wrote on sidst redigeret af
      #14

      Genmab/JPMorgan: Estimaterne ligger for højt inden årsregnskab https://www.proinvestor.com/investornyt/1111231/genmab-jpmorgan-estimaterne-ligger-for-hojt-inden-arsregnskab

      1 Reply Last reply
      0
      • E Offline
        E Offline
        E_L
        wrote on sidst redigeret af
        #15

        Lundbeck er ikke klar til at give op på CNS-kandidat
        Lundbeck vil nu holde møder med myndighederne om, hvad det næste skridt på vejen kan være for CNS-kandidaten Lu AF82422. Et muligt pivotalt studie kan være på bordet. https://medwatch.dk/Medicinal___Biotek/article16808042.ece

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #16

          “The outcome of the trial is encouraging, despite not reaching statistical significance,” insisted Johan Luthman, head of R&D at the Denmark-headquartered group. “We will now finalise the analysis of the data and plan the next step for progressing the Lu AF82422 MSA programme in dialogue with health authorities,” he added. https://pharmaphorum.com/news/lundbeck-study-knocks-confidence-alpha-syn-cns-target

          1 Reply Last reply
          0
          • Y Offline
            Y Offline
            YPE
            wrote on sidst redigeret af
            #17

            Er der ikke kæmpe støtte på det her niveau? Jeg er ikke stærk teknisk overhovedet, men hvis man tror på statistikken, så skal den op herfra.

            1 Reply Last reply
            0
            • BulderB Offline
              BulderB Offline
              Bulder
              wrote on sidst redigeret af
              #18

              Jeg kan ikke tælle hvor mange gange der af TA’ere er blevet sagt “ op herfra” det sidste halve år.

              1 Reply Last reply
              0
              • P Offline
                P Offline
                Pensionisten
                wrote on sidst redigeret af
                #19

                😄

                1 Reply Last reply
                0
                • K Offline
                  K Offline
                  Klarussen
                  wrote on sidst redigeret af
                  #20

                  The Trend is not your Friend as Genmab shareholder

                  1 Reply Last reply
                  0
                  • J Offline
                    J Offline
                    JKY_VH
                    wrote on sidst redigeret af
                    #21

                    haha Klarussen, ikke helt skævt

                    1 Reply Last reply
                    0
                    • BulderB Offline
                      BulderB Offline
                      Bulder
                      wrote on sidst redigeret af
                      #22

                      Rally i US. NASDAQ +1,3%. Gode teknikregnskaber. NASDAQ future +2,2%. VIX -3%

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        Riis7
                        wrote on sidst redigeret af
                        #23

                        Meta oppe med 14 %

                        1 Reply Last reply
                        0
                        • S Offline
                          S Offline
                          Sukkeralf
                          wrote on sidst redigeret af
                          #24

                          A Phase 1/2, Open-label, Dose-finding Trial With Expansion Cohorts to Evaluate the Safety and Antitumor Activity of GEN1056 (IgG1-PD1) as Monotherapy or Combination Therapy With GEN1042 in Subjects With Advanced Solid Tumors.

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #25

                            Mon target for GEN1056 afsløres lidt her?

                            1 Reply Last reply
                            0
                            • Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktørH Offline
                              Helge_LarsenPI-redaktør
                              wrote on sidst redigeret af
                              #26

                              Godmorgen. Ny rekord i januar og ATH med 103.000 unikke besøgende på Proinvestor.com 🙂

                              1 Reply Last reply
                              0
                              • Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktørH Offline
                                Helge_LarsenPI-redaktør
                                wrote on sidst redigeret af
                                #27

                                Tak for indsatsen til alle jer skrivende brugere og til jer som læser med. 🙂

                                1 Reply Last reply
                                0
                                • L Offline
                                  L Offline
                                  LP90
                                  wrote on sidst redigeret af
                                  #28

                                  Godmorgen 🙂

                                  1 Reply Last reply
                                  0
                                  • B Offline
                                    B Offline
                                    bibob
                                    wrote on sidst redigeret af
                                    #29

                                    God morgen. 🙂

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #30

                                      Nivolumab is IgG4 PD-1 , isnt't it? and Pembrolizumab

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #31

                                        not sure where you found that Sukkeralf, but would be another confirmation of GEN1042 also then if that is a new trial?

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #32

                                          annual US price change for Darzalex 6.3%, Tecvayli 5.0%, Rybrevant 4.0% (Sarclisa was +2.5%, like last year when Sanofi also did another hike in the summer)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper